Background: in Canada, gay, bisexual and other men who have sex with men (GBM) are disproportionately affected by HIV. Use of HIV pre-exposure prophylaxis (PrEP) by GBM for whom PrEP is clinically recommended, is unknown. We report on PrEP access and factors associated with not using PrEP, among HIV-negative/unknown GBM in Montreal, Toronto and Vancouver. Methods: from 2017 to 2019, the Engage study recruited sexually-active GBM≥16 years in Montréal(M), Toronto(T), and Vancouver(V) via respondent-driven sampling (RDS). Participation included HIV/STI testing and a questionnaire. We examined PrEP access using a health services model and fit RDS-adjusted logistic regressions to determine correlates of not using PrEP among those who were PrEP-a...
OBJECTIVE:Currently, HIV pre-exposure prophylaxis (PrEP) is not covered by health insurance in the N...
IMPORTANCE, Emerging evidence suggests that risk of bacterial sexually transmitted infections, STIs,...
Pre-exposure prophylaxis (PrEP) has been shown to prevent as many as 90% of HIV cases, yet it is not...
Gay, bisexual, and other men who have sex with men (gbMSM) are at the highest risk for HIV infection...
Background: Post-exposure prophylaxis (PEP) is currently recommended after certain high-risk exposur...
This study examined HIV testing and use, familiarity, and attitudes toward pre-exposure prophylaxis ...
recommended after certain high-risk exposures, and pre-exposure prophylaxis (PrEP) is undergoing eva...
Notwithstanding the efficacy of oral pre-exposure prophylaxis (PrEP) in clinical trials, a number of...
Using cross-sectional survey data (Engage, 2017-2018) from 1,137 men who have sex with men, ≥16 year...
IntroductionSingle-tablet combination emtricitabine/tenofovir is highly effective as HIV pre-exposur...
Introduction: Identifying appropriate pre-exposure prophylaxis (PrEP) candidates is a challenge in p...
Pre-exposure prophylaxis (PrEP) has altered the public health landscape for gay, bisexual, and other...
Background Data for on-demand pre-exposure prophylaxis (PrEP) are scarce. We implemented a cohort st...
IntroductionSingle-tablet combination emtricitabine/tenofovir is highly effective as HIV pre-exposur...
Objective: Currently, HIV pre-exposure prophylaxis (PrEP) is not covered by health insurance in the ...
OBJECTIVE:Currently, HIV pre-exposure prophylaxis (PrEP) is not covered by health insurance in the N...
IMPORTANCE, Emerging evidence suggests that risk of bacterial sexually transmitted infections, STIs,...
Pre-exposure prophylaxis (PrEP) has been shown to prevent as many as 90% of HIV cases, yet it is not...
Gay, bisexual, and other men who have sex with men (gbMSM) are at the highest risk for HIV infection...
Background: Post-exposure prophylaxis (PEP) is currently recommended after certain high-risk exposur...
This study examined HIV testing and use, familiarity, and attitudes toward pre-exposure prophylaxis ...
recommended after certain high-risk exposures, and pre-exposure prophylaxis (PrEP) is undergoing eva...
Notwithstanding the efficacy of oral pre-exposure prophylaxis (PrEP) in clinical trials, a number of...
Using cross-sectional survey data (Engage, 2017-2018) from 1,137 men who have sex with men, ≥16 year...
IntroductionSingle-tablet combination emtricitabine/tenofovir is highly effective as HIV pre-exposur...
Introduction: Identifying appropriate pre-exposure prophylaxis (PrEP) candidates is a challenge in p...
Pre-exposure prophylaxis (PrEP) has altered the public health landscape for gay, bisexual, and other...
Background Data for on-demand pre-exposure prophylaxis (PrEP) are scarce. We implemented a cohort st...
IntroductionSingle-tablet combination emtricitabine/tenofovir is highly effective as HIV pre-exposur...
Objective: Currently, HIV pre-exposure prophylaxis (PrEP) is not covered by health insurance in the ...
OBJECTIVE:Currently, HIV pre-exposure prophylaxis (PrEP) is not covered by health insurance in the N...
IMPORTANCE, Emerging evidence suggests that risk of bacterial sexually transmitted infections, STIs,...
Pre-exposure prophylaxis (PrEP) has been shown to prevent as many as 90% of HIV cases, yet it is not...